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ABSTRACT
Autism spectrum disorders (ASD) are associated with defects in neuronal connectivity and are
highly heritable. A significant proportion of ASD cases are of complex genetic etiology; complexity
which might reflect the impact of gene-environment interactions. However, there is a gap in our
understanding of the mechanisms that underlie the gene-environment interaction in autism
complex etiology. Genome wide association studies in large ASD cohorts identified high risk
variants associated with autism in genes that regulate histone modifications and remodel
chromatin. These findings highlight the relevance of chromatin regulatory mechanisms in the
pathology of ASD. Changes in Histone H3 methylation have been identified in a subset of neuronal
genes in postmortem cerebral cortex of autism patients. ASH1L is a histone H3-methyltransferase
that was previously identified in whole exome sequencing studies, as a gene strongly enriched for
variants likely to increase ASD risk. However, the role of ASH1L during human neurodevelopment is
not well understood on a cellular or molecular basis. To investigate ASH1L during human brain
development, I analyzed developmental transcriptome data collected from donated post-mortem
human brain tissue; tissues that was processed in the Allen Brain Atlas. My analysis suggests that
ASH1L is active during early prenatal development, along with other genes important to chromatin
modification. Furthermore, I find that co-expression network analysis implicates ASH1L in a cluster
of genes important to the development of neuronal projections, protein ubiquitination, and
neurotrophin signaling pathways. This analysis supports cellular and molecular phenotypes seen in
ASH1L knockdown studies performed in human-induced neurons. Through these analyses, ASH1L is
shown to be important both in early neurodevelopment, and to be strongly associated with ASD
pathology.
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INTRODUCTION
ASD is a common neurodevelopmental disorder and growing public health concern. On average the
cost of taking care of an individual with ASD is about $1.4 million dollars per individual during their
lifetime (Baio, 2018). A recent study by the CDC reports that ASD affects 1 in 59 children aged 8
years in 2014. The latest findings provide evidence that the prevalence of ASD is higher than
previously reported estimates. An increased prevalence means there is an increasing number of
families in the United States in need of services, and in search for viable bio-therapeutic options to
improve the lives of their children with ASD (Baio, 2018). To develop therapeutic options, the
mechanisms underlying autism-associated phenotypes must be better understood through
research.

ASD are defined diagnostically by impaired social interactions, language deficits, and restricted or
repetitive patterns of thought and behavior, present early in a child’s development (Reynolds and
Kamphaus, 2013). These phenotypes are thought to result from disordered neurodevelopment,
although the precise etiology is not known. The challenge of understanding ASD’s etiology stems,
to an extent, from the pathology’s strong genetic heterogeneity. Hundreds of genes have been
linked to ASD, but only a few reproducible genetic variants have recurrent and statistically
significant evidence linking them to ASD (Loke et al., 2015).

The Simons Foundation Autism Research Initiative (SFARI) gene scoring panel annually reviews
published literature on the genetics of autism to assess the strength of the evidence linking
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candidate genes to ASD. Genes in category 1, the high confidence category, are genes with the
strongest evidence to be linked with ASD. To be placed in the category independent studies must
have rigorous statistical comparison between cases and controls yielding genome-wide statistical
significance for a specific genetic mutation and ASD (Abrahams et al., 2013). SFARI ASD gene
database has identified 25 genes with de-novo rare mutations to be category 1 genes, genes with
the highest association with ASD. Eight of these category 1 genes are chromatin regulatory genes,
genes important to the regulation epigenetic landscape of neurodevelopment. Epigenetic
programs are important to embryonic and subsequently neuronal development as they orchestrate
series of events that require spatiotemporal control (Habibi and Stunnenberg, 2017). Specifically,
epigenetic proteins are important in mediating the response to environmental cues that initiate
processes such as neurogenesis, neuronal migration, gliogenesis, and synaptic formation.

One chromatin-modifying and category 1 gene, ASH1L, has been associated with Autism. Both
frameshift and missense de-novo loss-of-function (LoF) ASH1L variants have been reported in
individuals with ASD (De Rubeis et al., 2014; Willsey et al., 2013, Tammimies et.al 2015 ). In clinical
studies of small cohorts of children LoF mutations in ASH1L, phenotypes such as intellectual
disability, speech difficulties, mild thickening of the corpus callosum, microcephaly, as well as facial
and skeletal abnormalities have been reported (Okamoto et al., 2017; Shen et al., 2019; Stessman
et al., 2017). However, the impact of these ASH1L variants on protein function and cellular
processes have yet to be determined.
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ASH1L Molecular Function:
ASH1L is a histone methyl-transferase known to di-methylate H3K36 and H3K4 in humans. The
protein is a member of the Trithorax group of proteins (TrxG), a group of well known chromatin
modifying factors associated with gene activation during development (Miyazaki et al., 2013).
ASH1L, as a TrxG member, plays a vital role in maintaining Hox gene expression and correct skeletal
formation during embryonic development. Best understood in Drosophila, the methylation of
H3K36 by ASH1L promotes the binding of the H3K4 methyltransferase complex, COMPASS, to the
H3K4 mark, and subsequent methylation of the mark by MLL3 (Schuettengruber et al., 2017). The
methylation of H3K36 and H3K4 histone marks modify chromatin structure allowing for the
activation of transcription of target genes. Counteracting these TrxG methyltransferases, are
demethylases such as KDM2B. KDM2B specifically demethylates H3K36me2 marks deposited by
ASH1L, while also recruiting the non-canonical Polycomb repressive complex 1 (PRC1) which leads
to gene repression or inactivation (Corley and Kroll, 2015). The PRC1 complex is a member of the
Polycomb Group (PcG), which acts antagonistically to TrxG protein complexes, to orchestrate the
expression and repression of key genes during embryonic development. In addition to the PRC1
complex, the PcG also contains the Polycomb repressive complex 2 (PRC2) complex, made of the
catalytic subunits EZH2, EED, and SUZ1/2 (Schuettengruber et al., 2017). The methylation of H3K36
by ASH1L has also been reported to inhibit the catalytic activity of PRC2 (Huang and Zhu, 2018).
Together TrxG and PcG proteins work in opposition to coordinate developmental processes across
species through epigenetic modification.
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Given the strong implication of ASH1L in neurodevelopmental disease pathogenesis, it is important
to understand the mechanisms by which ASH1L operates specifically during brain development.
Despite all that is known about PcG protein complexes, less is understood about the spatiotemporal
function of ASH1L during neurodevelopment.
The Role of PRC2 in Neuronal Development
Prenatally, the PRC2 complex, is known to be highly expressed in neural progenitor cells in the
ventricular zone, the proliferative region in the developing brain helping to maintain pluripotency
and prevent differentiation during the brain’s neurogenic phase (Fig.1). The PRC2 complex prevents
neuronal differentiation through the tri-methylation of H3K27 mark near neural fate genes like
NGN1 and GFAP. Deletion of EZH2, the PRC2 catalytic subunit, during embryonic development
leads to precocious neuronal differentiation and astrogliogenesis (Corley and Kroll, 2015). PRC2
proteins also promote proliferation during cerebellum formation, gliogenesis, and adult
neurogenesis. Expression of EZH2 is high in oligodendrocyte and cerebellar progenitor cells (Liu et
al., 2018). In postnatal brains, the expression of EZH2 promotes proliferation through the inhibition
of PTEN in the hippocampus, and the expression of another PRC2 catalytic subunit, EED, maintains
neuroblast pluripotency in the olfactory bulb (Liu et al., 2018; Sun et al., 2018). Not only is PRC2
important to proliferation, it is important in preventing neuronal cell death. As a person ages, PRC2
activity leads to increased levels of H3K27me3 marks on genes important to cell death and
transcriptional regulators (PMAIP, BOL, CDKN2A, GATA6) in human neurons (von Schimmelmann et
al., 2016). PRC2’s role in the repression of apoptotic genes and activation of proliferation genes in
the brain, has also been implicated in glioblastoma and myeloid malignancies (Ronan et al., 2013)
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Figure 1. Human Cortical Development. Budday et.al. Front.Cell Neurosci. 2015; 9:257

Finally, recent studies have found PRC2 to play an important role in establishing activity dependent
neuronal morphology. The conditional knockout of a H3K27 demethylase gene, KDM6A, in mice
showed that the knockout led to abnormal neuronal morphology, cognitive deficits, and decreased
expression of genes critical for synaptic plasticity (ACTN2, EGR3, TGFB2, NOS1). Abnormal neuron
morphology is an attribute often associated with ASD, a disease PcG proteins have been associated
with. Deletion mutations in the H3K27me2 demethylase, JARID2, has been highly associated with
ASD (Liu et al., 2018). Furthermore, a study of chromatin modifier, CHD8, in neural progenitor cells
found that CHD8 binds to the promoters of EZH2 and Suz12, promoting PRC2 repression of neural
genes. When functional, CHD8 ensure the generation of appropriate number of neurons during
cortical development. When mutated, CHD8 upregulates PRC2 target genes and leads to the
outgrowth of the cortex (Durak et al., 2016). Interestingly, studies have shown CHD8 to also be a
highly associated-ASD risk gene with gene targets strongly enriched for other ASD-risk genes,
including ASH1L (Cotney et al., 2015)
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ASH1L in Neuronal Development
Unlike PcG proteins, ASH1L’s function and interaction in epigenetic networks during development is
not a well understood. In mice, ASH1L knock-out was shown to be embryonically lethal, while
heterozygous mutants had severe skeletal abnormalities. Outside of the nervous system, ASH1L
targets genes important for muscle cell differentiation, many of which are also Polycomb target
genes, in human myoblasts (Castiglioni et al., 2018). Within the nervous system, ASH1L has been
shown to regulate the transcription of NRXN1α in response to neuronal activity (Zhu et al., 2016b).
The effect of ASH1L prior to synaptogenesis is under investigation in the laboratory of Dr. Sofia
Lizarraga. ASH1L shRNA knockdown (KD) experiments performed in human embryonic stem cellderived neurons, show a decrease in overall neurite length and neural arborization. These
phenotypes are correlated with the downregulation of the gene encoding for the neurotrophin
receptor TrkB (NTRK2) in ASH1L KD neurons. However, the mechanism behind this observed
phenotype has yet to be discovered.

The primary goal of my thesis work is to gain a better understanding on the molecular pathways
that might be associated with ASH1L and that might be relevant to its neuronal function. Many
fundamental questions surrounding ASH1L’s role in brain development currently exist. For
example, where and when is ASH1L expressed in the developing human brain? Does ASH1L
regulate neuronal function by counteracting the activity of PcG complexes? Does ASH1L regulate
pathways associate with neuronal morphogenesis or cell fate? My thesis aims to investigate these
questions by: (i) investigating where in the brain and at what levels is ASH1L expressed during
human development; (ii) comparing the expression of ASH1L in the human prefrontal cortex to the
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expression of other chromatin modifiers in the TrxG and PcG complexes; (iii) exploring the potential
co-expression networks within the dorsolateral prefrontal cortex during early prenatal brain
development. In this manner, my thesis work, will help to better understand the neuronal
morphogenesis phenotypes seen in the ASH1L KD experiments, as well as elucidate associations
between ASH1L-related co-expression networks and ASD-risk co-expression networks.
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MATERIALS AND METHODS:
Developmental Transcriptome Data Analysis
Gene expression data was obtained from the Allen Brain Atlas Developmental Transcriptome
Database (Miller et al., 2014). Transcriptome data was obtained from RNA-sequencing and exon
microarray hybridization that was generated across 13 developmental stages and 8-16 brain
structures. RNA-sequencing was performed in human brain specimens collected by the
Department of Neurobiology at Yale School of Medicine and the National Institute of Mental
Health. Postmortem brains were collected from individuals ranging from 8 post-conceptional
weeks (pcw) to over 40 years of age and were selected according to criteria that would ensure
consistency between samples; i.e. brains with chromosomal abnormalities, malformations,
neuronal loss, or associations with alcohol abuse and neurological disease were excluded from
analysis. Eligible tissues were screened for high RNA quality and cytoarchitectural integrity. Tissue
and RNA sequencing preparation, and processing were performed as described by the Allen Brain
Reference Atlas. In total, expression data was collected from 37 different donors; 21 males and 16
females, across the human lifespan.

Expression heat maps were generated using RNA-sequencing expression values downloaded from
the Developmental Transcriptome database for genes of interest. Expression values, age of donor,
and brain structure were further analyzed using Broad Institute’s Morpheus software
(https://software.broadinstitute.org/morpheus). The colors on the heat map range from dark blue,
representing low expression, to bright red representing high expression, as ranked based on
expression values contained in each row. Each column represents brain tissue from one donor;
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apart from a few columns, where there were multiple donors for one age. In these cases, the
expression was averaged from donors of the same age (12pcw, 13pcw, 16pcw,4 months, 3 years) in
order to improve the visualization of age-related expression trends. Donor information can be
found in Appendix A. Expression data was not available for every brain structure for each donor, as
denoted by the gray boxes in the heat map. Average expression, hierarchical clustering, and box
and whisker plots were calculated and created using the Morpheus software.

Gene Correlation Study
To elucidate genes with similar expression patterns to ASH1L and other genes of interest in the
study, the correlative search option within the Developmental Transcriptome Database was used.
This function finds genes with similar expression patterns over the entire dataset or over a subset of
structures and developmental stages ( Allen Brain Atlas, 2017). For this study correlative genes
were found over a time frame of 8-37pcw, the time frame which corresponds to prenatal
development. Furthermore, the correlative search focused on structures of the prefrontal cortex
(PFC): dorsolateral prefrontal cortex (DFC), ventrolateral prefrontal cortex (VFC), anterior (rostral)
medial prefrontal cortex (MFC). The top 500 genes with the highest positive correlation (r) to
ASH1L gene expression in the DFC, VFC, and MFC during 8-37pcw were analyzed (0.741<r < 0.959).

Functional Enrichment Analysis of Correlation Data
To analyze the function of top correlated genes Toppgene Suite ToppFun software
(https://toppgene.cchmc.org/enrichment.jsp) was used to detect functional enrichment of these
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top genes based on Transcriptome, Proteome, Ontologies (GO, Pathway), Phenotype (human
disease and mouse phenotype), and literature co-citation (Chen et al., 2009). Genes were imported
into the portal, correction was set and resulting functional enrichments were given in tabular form
and ranked by P-value.

Co-expression Network Construction and Data Visualization
ASH1L co-expression networks were created using the correlative search method, and modelled
after the ASD co-expression network construction method performed by Willsey et.al (Willsey et al.,
2013). First, the top 20 positively correlated and top 15 anti-correlated genes with ASH1L in the DFC
during 8-16pcw timeframe were found. The expression data in this timeframe came from ten
different donors. Next a correlative search for each of the 35 genes, identified above, was
performed. The correlated genes with R-values above 0.97 or below -0.97 were recorded for each
gene. In total 1270 gene pairs and corresponding R-values were used to construct the ASH1L coexpression networks.

To visualize the co-expression data, the data was uploaded to STRINGdb (https://string-db.org/) .
Protein interaction networks were further elucidated by modifying the minimum interaction score
to high confidence, this modifies the network to only show gene interactions that exhibited a score
of 0.7 and above. STRINGdb predicts the strength of gene interactions based on a combined score
computed from probabilities from different evidence channels and correcting for probability of
randomly observing the interaction (Szklarczyk et al., 2015). The correlative and anti-correlative coexpression networks for ASH1L were computed separately.
11

CHAPTER 1
ASH1L GENE EXPRESSION PATTERNS DURING HUMAN BRAIN DEVELOPMENT
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ASH1L is Highly Expressed in Early-Mid Fetal and Late Adolescent Brains
Developmental Transcriptome data collected from human brain tissue specimens in different areas
of the brain and at different stages of development is useful in helping to understand where and
when a gene may be important to human neurodevelopment. Non-intronic ASH1L expression data
from the Developing Human Brain Atlas is visualized in a heatmap (Fig. 1A). As indicated by the red
coloration in the heat map, high expression values are seen predominantly during mid fetal
development and adolescence for most structures. There is a notable region of low expression for
most brain structures from 2-4 years of age. Exceptions to this trend are seen in the cerebellar
cortex (CBC) and the mediodorsal nucleus of the thalamus (MD), where higher expression is seen
later from 4-15 years and 18-40 years respectively. Interestingly, in Willsey’s study of ASD coexpression networks, a MD-CBC network was found to be highly enriched for ASD-associated genes
from the period of birth to six years of age (Willsey et al., 2013). The MD-CBC co-expression
network within this time period and region included ASH1L, among other ASD-associated genes,
such as NRXN1 which also has been shown to be regulated by ASH1L (Zhu et al., 2016b). Therefore,
analysis of ASH1L expression correlates with previously published data sets

Analysis of the heat map showed that the highest average expression of ASH1L during the human
lifespan was in the CBC. The lowest average expression of ASH1L in the MD (Fig.2A). The MD-CBC
structures and association with ASH1L is interesting. However, I decided to focus on the structures
of the prefrontal cortex (PFC) because there is evidence suggesting a role of the PFC in autism
pathogenesis, and because our in-vitro neuronal data on ASH1L was obtained in human cortical
neurons (Donovan and Basson, 2017). The average expression of ASH1L in each of the structures of
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the prefrontal cortex (DFC, VFC, MFC, OFC) was roughly the same, 3.05 ± 0.05 (log2) reads per
kilobase of transcript (RPKM), (Fig.2B and Fig. 2D). Temporally, ASH1L was most highly expressed
during prenatal development in the brains of donors with ages of 9pcw-16pcw, a timeframe that
was confirmed to be significant after performing hierarchical clustering of the average expression
values across the columns of the heat map (Fig.2C).

The Brain Atlas is useful in understanding gene expression on a larger scale, as it focuses on total
expression in one brain structure. The atlas, however, does not provide information on what type
of cells within the brain structure are expressing ASH1L, and what proportion of the ASH1L positive
cells make up the entire structure. A cellular-based study would be of interest, especially during the
5pcw-15pcw when the cerebral cortex is undergoing neurogenesis, radial migration, and neuronal
differentiation. During this period the brain is made of radial glial cells (RGCs), apical and basal
intermediate progenitor cells, and early born post-mitotic neurons (Budday et al., 2015). A study of
the epigenetic factor landscape in the developing mouse brain found that ASH1L was specifically
enriched in apical and basal intermediate progenitor cells , while members of the MLL complex
(H3K4me3-depositing complex) and demethylases were enriched in post-mitotic neurons, and
members of the PRC2 complex were enriched in RGCs ( Elsen et al., 2018).

Intermediate progenitor cells (IPC) are unpolarized cells in the ventricular and subventricular zone
that divide symmetrically to generate upper neocortical layers, and influences cortical thickness
(Pontious et al., 2008). IPCs also found in the intermediate zone, an area of white matter where
neurons made in the ventricular zone migrate through in order to reach the cortical plate during
14

corticogenesis. This area eventually transforms into adult white matter (24pcws onwards) (Budday
et al., 2015). Delayed myelination and microcephaly are phenotypes associated with de-novo
mutations in ASH1L, and perhaps tied to disturbances in ASH1L expression in IPCs during critical
points in the development of the neocortex. ASH1L may be important to the formation of the
white matter of the intermediate zone and the migration of neurons across this white matter to the
cortical plate. In the future I would analyze the expression of ASH1L using Allen Brain Atlas
microarray data collected from the cortical plate and ventricular zone during human brain
development the cortical plate and ventricular zone. This would allow ASH1L expression to be
studied more on a cortical layer-based level, rather than brain structure-based level.
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A

ASH1L Expression Across Lifespan
MFC OFC

-log2 RPKM

DFC VFC

Brain Structure
Age
8 pcw
9 pcw
12 pcw
13 pcw
16 pcw
17 pcw
19 pcw
21 pcw
24 pcw
35 pcw
37pcw

Avg. Expression
2.3
3.41
3.33
3.46
3.36
3.03
2.43
3.37
2.81
2.05
2.44

D

ASH1L Expression Across Lifespan

DFC VFC MFC OFC

-log2 RPKM

C

Brain Structure

Figure 2. ASH1L expression analysis at pre and post-natal stages (A) ASH1L Expression Heat Map
where each box represents the ASH1L expression level at one specific age in one structure of the
brain. Red represents high levels of expression, while blue represents low levels of expression. The
gradient is calculated over the entire period of development (all the columns). Grey boxes indicate
no expression data was available for analysis. (B) Box-and-whisker plots shows median values of
expression of ASH1L across the lifespan of the individual starting at fetal stages in the four
structures of the PFC. Points outside of the box represent outlier data values. (C) ASH1L Expression
Heat Map over prenatal brain developmental period. The table corresponds to the average
expression of ASH1L at each age during prenatal development; green coloration represents higher
expression and red represents low expression. (D) Box-and-whisker plots of gene expression in the
PFC structures during prenatal development.
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ASH1L DFC Prenatal Expression is similar to that of MLL and Demethylases of PcG Complexes
As a methyltransferase and TrxG member, ASH1L is also a member of the epigenetic factor
landscape of development. However, ASH1L’s modulation of the epigenetic landscape during
neurodevelopment is not fully understood, but expression data can be used to compare ASH1L to
other TrxG and PcG genes (Fig.3A-B). ASH1L expression data from one brain structure, the DFC, was
used for the comparative analysis between ASH1L and TrxG or PcG genes. The DFC was chosen
because all donors with ages in prenatal development had expression values for this structure, also
the DFC is of interest due to its relation to ASD phenotypes. By comparing ASH1L’s expression to the
expression of the genes of these complexes, we can discover the genes expressed most similarly to
ASH1L which can implicate potential molecular interaction of these genes or suggest epigenetic
mechanisms at a specific time point in brain development.

The MLL complex is a TrxG complex, known to interact with ASH1L. The complex contains MLL3 or
KMT2C, an ASD-associated gene, which similar to ASH1L, is a histone methyltransferase (H3K4me3)
important to gene activation and implicated in neuronal differentiation (De Rubeis et al., 2014;
Elsen et al., 2018; Schuettengruber et al., 2017). The histone mark, H3K4, can be demethylated by
three proteins: KDM1A, KDM5B, KDM2B. In contrast, ASH1L’s histone mark, H3K36, has one
demethylated by KDM2B. My analysis shows that ASH1L is expressed in similar levels to KDM2B,
and MLL3. Similarly, expression of KDM1A and KDM5B are higher than the other genes, suggesting
that there might be greater demethylase activity rather than methylase activity in the DFC during
this time period (Fig.3C). Moreover, target genes of MLL3 during this time period may be more
likely to be repressed given higher levels of H3K4 demethylase expression. Hierarchical clustering
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further validates the similarities observed between the methyltransferases and demethylases
(Fig.3C).

The PRC1 complex is responsible for the mono-ubiquitination of lysine 119 on histone H2A,
(H2AK119), and canonical recruitment of the PRC2 complex (Schuettengruber et al., 2017). The
complex is made up of different components depending on its function. Canonically, PRC1 leads to
repression of genes through its recruitment of the PRC2 complex; the non-canonical PRC1 complex
is different. The H3K36 demethylase, KDM2B, recruits the PRC1 non-canonical complex (RYBP,
PCGF3/5, RBBP7, RING1), and then recruits the PRC2 complex and promote gene repression. (Corley
and Kroll, 2015). I find that most of the PRC1 components are expressed at higher levels than
ASH1L during prenatal development, except for PCGF5. ASH1L is linked through hierarchical
clustering to PCGF3 both in prenatal development (Fig.3D) and first-early second trimester
development (Fig.3B). The first-early second trimester development association is also notable as
PCGF5 is most closely clustered with KDM2B, then ASH1L (Fig. 3B). Further analysis of the PRC1
complex, KDM2B, and ASH1L, could help to elucidate the mechanistic link between the two
epigenetic antagonistic complexes during neuronal development.

In addition to the PRC1 and MLL complexes, the PRC2 complex is also active during prenatal brain
development, especially during early fetal development. I find that members of the catalytic
component of the PRC2 complex (EED, RBBP7 SUZ12, and EZH2) have a high early expression trend
that drops off significantly around 13pcw (Fig.3E). The timing of expression in the DFC is supported
by studies that have shown the PRC2 complex to be most active during neurogenesis and cell
18

proliferation (Corley and Kroll, 2015). EZH1 has the opposite trend, increasing significantly in
expression at the end of prenatal development. This observation in consistent with findings that
suggest EZH1 contributes to the maturation of post-mitotic neurons (Liu et al., 2018). Our analysis
also indicates that EZH2 is notable for its range in expression during prenatal DFC development.
Being the catalytic driver of the PRC2 complex, responsible for the orchestration of proliferation
and differentiation developmental switches, it is unsurprising that EZH2 has such a large range of
expression.

The clustering analysis of the PRC2 complex expression during development implicates a
relationship between ASH1L and the H3K27 demethylases: KDM6A, and KDM6B (Fig.2E and Fig.2b).
One study found that the two demethylases were upregulated in IPCs and early born neurons of the
ventricular zone, and led to the de-repression of neuronal differentiation genes (Elsen et al., 2018).
Our analysis, which shows similar expression levels of H3K27 demethylases and ASH1L, also support
previous findings that report high expression of ASH1L in IPCs. Having similar expression levels to
genes expressed in the progenitor regions and important to neurogenesis, suggests that ASH1L may
have role in regulating proliferation/differentiation in neuronal stem cells; a role of ASH1L reported
in in mesenchymal and embryonic stem cells (Kanellopoulou et al., 2015; Yin et al., 2019). However,
the extent to which ASH1L regulates neuronal differentiation is largely unknown.

In conclusion, the comparative analysis performed here elucidates trends in expression that are
similar across different TrxG and PcG complexes. Clustering analysis during early prenatal
development, links methyltransferases of the PRC2 complex to subunits of the PRC1 complex.
19

Similarly, members of the TrxG complex (ASH1L and MLL3) cluster with PRC2 demethylases and
PCGF3 of the PRC1 complex (Fig.3B and Appendix B). Furthermore, looking at the three heat maps
(Fig 2C-E), ASH1L exhibits most similar expression patterns to that of the MLL complex (Fig 2A). This
finding correlates with the strong functional interaction of ASH1L and MLL observed in leukemia
cells (Zhu et al., 2016a). When studying ASH1L and its targets, it may also be important to consider
the MLL complex and its target genes.
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PRC1 Complex

E

PRC2 Complex

Average Expression (RPKM)

MLL Complex

Average Expression (RPKM)

C

Average Expression (RPKM)
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Figure 3. Comparison of MLL, PRC1, and PRC2 Complexes in the Development of the DFC. (A)
Hypothesized schematic of the TrxG and PcG interactions during chromatin remodeling. (B) Heat
map and hierarchical clustering of the expression of all TrxG and PcG relevant genes during 8-16pcw
of development (C-E) Heat map analysis, hierarchical clustering, and box-and-whisker plots of gene
expression for the relevant genes of the MLL, PRC1, and PRC2 complexes and ASH1L, shown
respectively in that order.
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CHAPTER 2
ASH1L CO-EXPRESSION PATTERNS IN THE PFC CORTEX DURING PRENATAL
DEVELOPMENT
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Transcriptome data is not only useful in understanding spatiotemporal patterns of gene expression,
it also can be used to generate gene co-expression networks. Co-expression network analysis is one
method used to infer potential gene function and gene-disease associations. This approach
constructs networks of genes with a tendency to show a coordinated expression patterns across a
group of samples, and subsequently analyzes these networks to elucidate functions of correlated
gene pairs and clustered modules. In this chapter, I present my studies in neuronal co-expression
networks associated with ASH1L expression during prenatal development.

ASH1L Positively Correlated Genes in the PFC Have Functional Enrichments Important to Neuronal
Projection Development
To further understand the function of ASH1L during neurodevelopment, a co-expression network
was created using the top 500 positively correlated genes to ASH1L, genes with r values above 0.74
in the PFC during prenatal development. The genes with expression most strongly correlated ASH1L
expression in the PFC over the prenatal period were KIF1B, BIRC6, EP300, and MLL5 (0.947<r
<0.959); KIF1B is a motor protein, BIRC6 is a E3 ubiquitin-protein ligase (anti-apoptotic protein),
EP300 is histone acetyltransferase (H3K27ac), MLL5 is a histone methyltransferase (H3K4me3).
Functional enrichment for the nodes (top correlated genes) of the network was performed using
ToppFun. Cellularly, the correlated genes were enriched in the nucleoplasm part of the cell in
addition to different parts of neuron (synapse, axon, dendrite). Genes in this network were also
highly significantly enriched in neuron projection, microtubule end, and growth cone of the cell
(Fig.4A). Gene Ontology for Biological Processes indicated significant enrichment in genes
important to epigenetic processes, such as histone modification, chromatin organization, and
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histone methylation, which fits into the canonical function of ASH1L. Enrichment analysis also
revealed that co-expressed genes were enriched in neuron development, neuron differentiation,
and interestingly neuron projection development and morphogenesis. Genes were also enriched in
the biological process of regulation of neuron projection development and cell projection
organization (Fig.4B).

The enrichments associated with cytoskeleton and neuronal morphogenesis are interesting in the
context of in-vitro ASH1L shRNA KD experiments performed by Seonhye Chen, of the Lizarraga lab,
in hESC-derived cortical-like neurons. I conducted morphometric analysis of ASH1L KD neurons
using Neurolucida software and found that shRNA transfected neurons exhibited abnormal
cytoskeletal features shorter neurite length and decreased branching in comparison to GFP controls
(Fig.4C-E). The underlying mechanism is not well understood, but the overrepresentation of genes
important to cell projection morphogenesis in the ASH1L co-expression network suggest that ASH1L
plays a morphometric role in neurodevelopment.

The hESC-derived neurons resemble early development (8-16pcw) dorsolateral prefrontal cortex
neurons (Mariani et al., 2015). Given this resemblance, a second ASH1L correlative search was
performed to find the top 500 genes in the DFC during 8-16pcw of development. Functional
enrichment yielded similar GO biological function and GO molecular function results, but these
genes were slightly more enriched for neuron projection development in the DFC (p-value= 9.41E14) and in the PFC (p-value=1.50E-13) (Appendix D).
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Figure 4. ASH1L might regulate neuronal morphogenesis (A)Stem cell derived H1 cortical neurons
at day 35 of neuronal induction were nucleofected with ASH1L-shRNAII+GFP constructs (top right
panel), ASH1L-shRNAIII+GFP (bottom right panel), ASH1L-shRNAIV+GFP (bottom left panel) GFP
construct alone (left panel). White arrows indicate longest neurite. (B) Histogram representation
of neurite length analysis shows a reduction in neurite length in ASH1L-shRNA-II, ASH1L-shRNA-III
and ASH1L-shRNA-IV compared to control GFP; ***p<3.00E-05 (C) Histogram representation of
branches per cell analysis shows a reduction in branches in ASH1L-shRNA transfected neurons
compared to GFP control; ***p<0.001 (D) GO Cellular Component Analysis of top 500 ASH1L
correlated genes in the PFC during prenatal development. (E) GO Biological Function Analysis of top
500 ASH1L correlated genes in the PFC during prenatal development
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ASH1L Top Correlated Genes in Fetal PFC Overlap with many ASD-risk Genes
The ASH1L co-expression networks were analyzed to find enrichment of disease-related genes. In
the PFC and DFC co-expression analysis, genes in both sets were enriched highly for intellectual
disability and Autism, and in the PFC for speech delay (Fig.5A-B). These associated disease
phenotypes are have been reported numerous times in clinical observations seen in patients with
de-novo ASH1L mutations (Okamoto et al., 2017; Shen et al., 2019). Genes in both networks also
showed to overlap with ASD-risk genes found in the SFARI database (Fig.5C-D). Forty-nine genes
were shared between the two co-expression networks and SFARI database genes (Appendix D).
Recent studies have found that ASD risk genes are co-expressed in the mid-fetal human cortex,
suggesting ASD-risk genes converge in a regulatory network during neurodevelopment (Cotney et
al., 2015). My co-expression analysis implicates ASH1L as potential member of this ASD-related
regulatory network.
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Figure 5. ASH1L Correlated Genes are enriched for disease phenotypes seen in ASD individuals
with de-novo mutations in ASH1L (A) Disease Functional Enrichment for top correlated genes in
the prenatal PFC; p-values associated with disease enrichment are found in Appendix C. (B) Disease
Functional Enrichment for top correlated genes in 8-16pcw (C) Overlap of the genes in both
correlative studies and genes from the SFARI database. The 49 genes at the intersection of the
datasets are represented in the table. (D) Eighty genes are represented at the intersection of DFC
correlated genes and SFARI genes (E) Diagrams of the DFC and PFC human brain tissue at 16pcw
used to perform the developmental transcriptome study in the Allen Brain Atlas
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CHAPTER 3
ASH1L DFC CO-EXPRESSION AND PROTEIN-INTERACTION NETWORK DURING 816PCW OF DEVELOPMENT
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Co-expression networks are limited in what they can communicate about gene interactions.
Networks are effectively only able to identify correlations an do not confer information on causality
or distinguish between regulatory and regulated genes. A method which may confer regulatory
information from co-expression networks, is the increasingly used method of differential coexpression analysis. This approach identifies genes with varying co-expression partners during
different conditions. Using a method like that of Willsey et.al, a differential co-expression network
was created manually using correlation data from the Allen Brain Atlas (Fig.6). Four co-expression
networks were generated using this method described in Figure 6, and then analyzed for significant
protein interactions within the network using the STRING database (Fig.7, Fig.8, Appendix E).
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Figure 6. Differential Co-Expression Network Creation Schematic
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ASH1L Protein Interaction Network is associated chromatin Modification, protein ubiquitination,
ASD pathogenesis, and neurotrophin signaling pathways
The network of positive correlates of the positive ASH1L correlated genes, which will be called the
positive network, is useful in understanding the interaction of groups of genes that co-activate with
ASH1L in early DFC development. STRING database was used to predict significant protein
interactions within the gene correlation data set (Fig.7). The interaction network was made from
141 of the 433 genes and had significant Protein-Protein Interaction (PPI) p-value of 0.000637,
meaning the proteins in this network have more interactions among themselves than what would
be expected for a random set of proteins of similar size, drawn from the genome. Such an
enrichment indicates that the proteins are at least partially biologically connected, as a group.

Functional enrichment in this network shows an overrepresentation of proteins important to
ubiquitination, cytoskeleton development, chromatin modification, and the neurotrophic signaling
pathways. The ubiquitination-related proteins are represented by the pink nodes in Fig.7. Studies
have shown targeted protein degraded through ubiquitination to be important during early
neuronal differentiation (Saritas-Yildirim and Silva, 2014). In the context of epigenetics,
ubiquitination performed by the PRC1 complex on H2AK119 has also been reported to be important
to neuronal differentiation (Yao et al., 2018). This functional enrichment is very interesting because,
as elaborated on in Chapter 1, ASH1L was clustered with the expression of the PCGF3 component of
the PRC1 complex. Significant enrichment for cytoskeleton-related proteins and biological
functions (microtubule binding, adherens junctions, tubulin binding) is also of interest given findings
in Chapter 2 that suggest ASH1L correlates are important to cytoskeleton development.
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Additionally, of interest, many of the nodes important to the cytoskeleton are also genes associated
with ASD, as indicated by the dark blue and maroon coloration.

Chromatin modifying enzymes are also overrepresented in the functional enrichment of this
network (yellow nodes in Fig. 7). The False Discovery Rate (FDR) was lowest for this Reactome
pathway (1.51 E-05) for all enriched pathways. ASH1L’s interaction with EP300 has an interaction
score of 0.709; the interaction scores in on a scale of 0-1 and is an approximate probability that a
predicted link exists between two proteins. The interaction between EP300 and ASH1L relates
ASH1L to the module of genes most associated to chromatin modification. EP300 has very high
interaction scores with KMT2C (MLL3) and CREBBP. MLL3, as mentioned in Chapter 1, is a TrxG
protein important to gene activation during neuronal differentiation. CREBBP is a histone
acetyltransferase which acetylates H3K27, antagonizing Polycomb silencing (Tie et al., 2014). The
relationship and co-activation of these genes may elucidate a network of chromatin modifier
important to turning on and off genes important in the development of the DFC. Future CHIP
studies could be performed to investigate ASH1L intersection with other proteins pertinent to
chromatin modification.

Finally, analysis of enrichment of Reactome pathways in this gene set, links the co-expression
network to downstream signaling pathways of the human neurotrophin signaling pathway
(Appendix H). This pathway involves the binding of neurotrophic factors such as BDNF, NT3, and
NGF to Trk receptors which initiates signaling cascades such as the MAPK signaling pathway (dark
green node in Fig.5) important to cellular differentiation and axonal outgrowth, Ubiquitin mediated
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proteolysis (pink nodes) important to retrograde transport, and P13K-AKT pathway whose
downstream genes are important in the regulation of actin cytoskeleton and cell survival (Kanehisa
Laboratories, 2018; Khotskaya et al., 2017). NTRK2, the gene encoding for the BDNF receptor, Trkb,
is an upstream regulator of the P13K-AKT pathways. The Lizarraga lab has performed QPCR analysis
on ASH1L KD neurons and found a downregulation of NTRK2 (Appendix G). Other Trk receptor
encoding genes such as NTRK1, showed no downregulation in KD neurons. The presence of Trkbpathway related genes within this co-expression network suggests that ASH1L may regulate genes
important to neurotrophic signaling. Furthermore, the neurotrophic signaling pathway’s
downstream effect on the regulation of actin cytoskeleton is relevant to understanding the
morphology seen in ASH1L KD neurons (Fig. 4A, Appendix F). In summary, the positive coexpression network helps elucidate potential protein interactions relevant to ASH1L, as well as the
functional importance of these interactions. Future studies can further investigate the presence of
these interactions under different conditions, such as different developmental stage, different brain
structure, or in a disease-state (ASH1L mutant or knock down).
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ASH1L Positive Correlates’ Co-Expression Network

Figure 7. Co-Expression Protein Interaction Network for the positively correlated genes of the
positive correlated genes of ASH1L in the DFC during 8-16pcw of development. Nodes represent
genes and edges represent interaction between two nodes. The thickness of the edges indicates
the strength of data support. The node colors and significance of the colors are summarized in the
adjacent legend. Grey nodes are nodes that are not enriched for any of the attributes described in
the legend. This network is like the Negative Correlates of the Negative Correlates of ASH1L coexpression network (Appendix E Fig.7). Both networks contain clusters of genes around EP300,
HERC1, PSMC2, and USP34.
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ASH1L Anti-Correlation Network
Interactions between anti-correlates of ASH1L provide valuable information about genes that are
inactive in the same pattern that ASH1L is activated. The anti-correlate co-expression network was
found by finding the positively correlated genes for each of the 15 ASH1L negatively correlated
genes. The co-expression network had a PPI p-value of 1.33E-15, meaning that the network
interactions are highly significant. Genes in this network are highly enriched for mitochondriarelated biological functions (green, cyan, purple, and pink nodes). There are also genes enriched in
processes important to neuronal migration such as axon guidance and regulation of SLITs and
ROBOs. The functional enrichment of these genes and their association with current literature on
ASH1L is not especially clear. Further research into the expression of these genes during ASH1L KD
experiments would be insightful in understanding ASH1L’s regulatory in activation and repression of
specific modules of genes
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ASH1L Anti-Correlates’ Co-Expression Network

Figure 8. Co-Expression Protein Interaction Network for the positively correlated genes of the
negatively correlated genes of ASH1L in the DFC during 8-16pcw of development. Clusters of
genes enriched for functions related to the mitochondria are seen in the lower left corner of the
network. Clusters of genes associated with axonal guidance and metabolism are seen to the upper
portion of the network. This network is like the Negative Correlates of the Positive Correlates of
ASH1L co-expression network (Appendix E Fig.8). Both networks contain clusters of genes around
NDUF34, PSMA2, PHF5A, and MRPL13.
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CONCLUSION

The transcriptomic analysis of the developing human brain provides new information into the
orchestration and activation of different networks of genes during different time points in
development. Here, we describe ASH1L’s predicted role in early neurodevelopment based on
developmental transcriptome data. ASH1L is highly expressed in most structures of the brain
during the early-mid fetal stage and again starting in adolescence. Furthermore, in the structures of
the PFC, ASH1L is seen to be expressed at similar levels and in pattern with the TrxG gene MLL3 and
demethylases on the PRC2 complex. The timing and similar expression of these genes may
elucidate the molecular mechanism of TrxG activation and PcG silencing, seen in other species.
Genes with expression patterns to ASH1L in specific contexts, like the co-expressed genes reported
in Chapter 2 and 3, are proteins that could be interacting partners with ASH1L or genes that ASH1L
helps to regulate through its function a chromatin modifier. Our analyses of these co-expression
network in the PFC and DFC, implicated gene clusters associated with neuronal cytoskeleton
development, chromatin modification, and neurotrophin signaling pathways.

Through transcriptome analysis, this study also finds that ASH1L is highly associated with ASD and
Intellectual Disability; a finding well supported by previously published GWAS ASD studies, clinical
case reports, ASD co-expression network studies. ASH1L, as an epigenetic modifier, can affect the
activation and repression of many genes in response to the environment and activity of other
chromatin modifying complexes. A de-novo LoF mutation in this gene can therefore affect a wide
range of genes and downstream processes; processes that can lead to the neurodevelopmental
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pathogenesis in individuals who acquire the mutation during early prenatal development. A better
understanding of ASH1L’s target genes and effect on cellular pathways is therefore important in
understanding the pathogenesis of LoF-related ASD and ID. Furthermore, ASH1L is reported here to
be associated with many other significant ASD-risk genes, thereby making the understanding of
ASH1L useful in understanding ASD pathogenesis of related and co-expressed ASD-risk genes.

Future studies should be performed to validate these transcriptome results in disease-state models,
like in ASH1L KD human neurons or ASH1L mutant mice. In these experiments, the perturbation of
ASH1L could lead to disturbances in genes most strongly correlated to ASH1L, or biological
processes enriched in these co-expression networks. Additional bioinformatic studies of ASH1L in
different brain regions, especially the MD-CBC would be an interesting direction to study. Changes
in co-expression patterns of ASH1L across different developmental time periods and/or brain
structures would further explain ASH1L’s role in human brain development. Finally, investigations
into ASH1L on the chromatin level, using CHIPseq and ATACseq will be useful in understanding
ASH1L target genes, some of which may be reported here, as well as understanding ASH1L’s
interaction with other histone marks and chromatin modifiers. Ultimately, my findings here provide
a glimpse into the complex yet important role ASH1L plays in human neurodevelopment
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APPENDICES:
APPENDIX A: Table 1. Developmental Transcriptome Donor Information
Developmental Period
1st Trimester (1-13 pcw)

2nd Trimester (14-26pcw)

3rd Trimester
Infantood (0-1 year)

Early Childhood (2-4years)

Childhood
Teenage Years

Adulthood

Donor ID
H376.IIA.51
H376.IIA.50
H376.IIB.50
H376.IIB.51
H376.IIB.52
H376.IIIA.50
H376.IIIA.51
H376.IIIB.50
H376.IIIB.51
H376.IIIA.51
H376.IIIB.53
H376.IVA.51
H376.IV.54
H376.IV.50
H376.IIA.51
H376.V.50
H376.V.53
H376.VI.50
H376.VI.51
H376.VI.52
H376.VII.51
H376.VII.51
H376.VIII.53
H376.VIII.52
H376.VIII.53
H376.VIII.50
H376.IX.51
H376.IX.50
H376.X.51
H376.X.50
H376.X.53
H376.X.52
H376.XI.60
H376.XI.50
H376.XI.52
H376.XI.53
H376.XI.54
H376.XI.56

Age
8 pcw
9 pcw
12 pcw
12 pcw
12 pcw
13 pcw
13 pcw
16 pcw
16 pcw
16 pcw
17 pcw
19 pcw
21 pcw
24 pcw
26 pcw
35 pcw
37pcw
4 months
4 months
4 months
10 months
1 year
2 years
3 years
3 years
4 years
8 years
11 years
13 years
15 years
18 years
19 years
21 years
23 years
30 years
36 years
37 years
40 years

Sex
M
M
F
F
F
M
F
M
M
M
F
F
M
M
F
F
M
M
M
M
M
F
F
F
M
M
M
F
F
M
M
F
F
M
F
M
M
F

Race
European
European
Asian
African American
Two or more races
European
European
Hispanic
European
Two
European
Hispanic
African American
White
African American
White
European
White
European
African American
African American
European
European
European
Hispanic
African American
African American
African American
African American
African American
European
European
European
African American
White
White
African American
African American
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APPENDIX B:

Figure 9. Clustering Analysis on the Expression Heat Map Constructed for genes of the PcG and
TrxG complexes during prenatal development of the DFC.
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APPENDIX C. ToppFun Results Top 500 Correlated Genes in the DFC during 8-16pcw period
GO: Molecular Functional Enrichment
protein-containing complex binding
GTPase activator activity
GTPase regulator activity
nucleoside-triphosphatase regulator activity
microtubule binding
transcription coregulator activity
enzyme activator activity
cytoskeletal protein binding
tubulin binding
guanyl-nucleotide exchange factor activity
chromatin binding
microtubule plus-end binding
Disease
Intellectual Disability
Mental Retardation
Low intelligence
Poor school performance
Mental deficiency
Global developmental delay
Autistic Disorder
Small head
Developmental delay (disorder)
Mental and motor retardation
Cognitive delay
GO BIOLOGICAL FUNCTION
regulation of small GTPase mediated signal transduction
neuron projection development
generation of neurons
neuron development
neuron projection morphogenesis
positive regulation of GTPase activity
neurogenesis
neuron differentiation
regulation of GTPase activity
cell morphogenesis involved in neuron differentiation
cytoskeleton organization
regulation of nervous system development
cell morphogenesis

P-VALUE
2.18E-12
6.48E-10
1.03E-09
8.03E-09
1.33E-08
4.37E-08
6.05E-08
8.44E-08
1.30E-07
2.77E-07
6.04E-07
1.34E-06
P-VALUE
3.75E-21
2.04E-13
2.57E-12
2.57E-12
2.84E-12
7.18E-12
1.63E-09
2.79E-09
4.05E-09
5.73E-09
5.73E-09
P-VALUE
4.40E-14
9.41E-14
1.69E-12
1.77E-12
1.96E-12
2.18E-12
1.27E-11
1.47E-11
3.48E-11
5.92E-11
9.70E-11
2.63E-10
3.68E-10
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APPENDIX D:
Table 2. SFARI Gene Overlap

Shared Gene Categories

Genes

Number
of Genes

ASH1L DFC 8-16pcw and SFARI Genes

ADARB1, ADCY5, AHDC1, ANK2,
31
ARHGAP33, CDC42BPB, CHD3, DNAH10,
DYRK1A, EXOC6B ,FGD1, GRID1,
KDM4B, KDM5B, KIF21B, MNT,
NCKAP5L, NFIX, NLGN2, NLGN3, NTRK3,
OPHN1, PACS1, PER1, PRR12, SHANK2,
ST8SIA2, SYNE1, SYNGAP1, SYNJ1, TSC1

ASH1L Prenatal Cortex (DFC, VFC, MFC 8-35pcw)
and SFARI Genes

AGAP1 ANK3 ATRX CACNA1A CLSTN2
CNTNAP5 CTNND2 ELAVL3 EP400
GIGYF2 GPR139 GRIN2B GSK3B IL16
KCNB1 MTOR MYO5A NAV2 NBEA
NCKAP5 NIPBL NSD1 SMARCC2 SYN3
TAF1L UNC79 VPS13B YEATS2 ZNF407
ZNF8 ZNF827

ASH1L Prenatal Cortex (DFC, VFC, MFC 8-35pcw),
ASH1L DFC 8-16pcw, and SFARI Genes

ASH1L ARHGAP32 MBD5 DYNC1H1
49
TCF20 CASK SETD1B MECP2 EP300 PHF2
SRRM4 NF1 BIRC6 POGZ HUWE1
ZSWIM6 TECTA ADNP TRIO CHD8
CREBBP TET2 ARID1B TANC2 NCOR1
ASXL3 HERC2 JMJD1C APC CLASP1
ZNF462 AUTS2 KAT6A GRIK3 CDKL5
MED13L DIP2C DLGAP1 SETD2 SRCAP
CACNA1E AMBRA1 SCN8A SETBP1 DST
RERE KDM6B AKAP9 WDFY3

31
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APPENDIX E:

Figure 10. Co-Expression Protein Interaction Network for the negatively correlated genes of the
negatively correlated genes of ASH1L in the DFC during 8-16pcw of development. Clusters of
genes are colored based on k-means clustering.

Figure 11. Co-Expression Protein Interaction Network for the positively correlated genes of the
negatively correlated genes of ASH1L in the DFC during 8-16pcw of development. Clusters of
genes are colored based on k-means clustering.
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APPENDIX F:

Figure 12. Neutrophin Signaling Pathway. Neurotrophin Signaling Pathway has three main
receptors which activated different pathways which lead to different effect on the function of a cell.
Trkb (encoded by NTRK2) is important to promoting synaptic plasticity, while Trkc triggers signaling
cascades important for regulation of actin cytoskeleton and ubiquitin mediated proteolysis. This
image was found in (Khotskaya et al., 2017)
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APPENDIX G:

Figure 13. Knockdown of ASH1L in stem cell derived human neurons significantly reduces the
expression of NTRK2 (gene encoding TrkB receptor). Human cortical neurons at day 35 of neuronal
induction were nucleofected with ASH1L-shRNA-II. Cells were subjected to puromycin selection for
3 days after nucleofection. Histogram shows gene expression analyzed by QPCR for several
chromatin regulatory factors previously associated with autism. We found the most significant
change in gene in expression for ASH1L and for NTRK2 compared to untransfected human neurons
(control). The average of three independent experiments is shown. These experiments were
performed by Seonhye Chen.
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APPENDIX H:
Functional enrichment tables for the positive co-expression network as calculated using STRINGdb.
This data was used to created Figure 7 and its figure legend.
Cellular Component
nucleus
nucleoplasm
postsynaptic density
axon
dendrite
nuclear lumen
somatodendritic compartment
cell projection
neuron projection
Function
chromatin binding
histone acetyltransferase activity
catalytic activity, acting on a protein
histone-lysine N-methyltransferase activity
ubiquitin-protein transferase activity
steroid hormone receptor binding
tubulin binding
insulin binding
transferase activity
nuclear receptor binding
histone demethylase activity
phosphatidylinositol binding
ion binding
phosphatidylinositol 3-kinase binding
transcription coregulator activity
transcription coactivator activity
cytoskeletal protein binding
histone methyltransferase activity (H3-K4 specific)
microtubule binding
insulin-like growth factor I binding

false discovery
rate
0.0052
0.0052
0.0052
0.0052
0.0052
0.0052
0.0052
0.0052
0.0052
false discovery
rate
0.0193
0.0193
0.0193
0.0196
0.0255
0.0288
0.031
0.031
0.0338
0.0338
0.0338
0.0338
0.0338
0.0338
0.0339
0.0339
0.0339
0.0339
0.0397
0.0397
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Cellular Process
cellular protein modification process
learning
cellular component organization
histone modification
macromolecule modification
cellular protein metabolic process
nervous system development
learning or memory
regulation of cell differentiation
regulation of multicellular organismal development
peptidyl-lysine modification
cellular macromolecule metabolic process
regulation of macromolecule metabolic process
chromatin organization
microtubule cytoskeleton organization
organelle organization
regulation of metabolic process
cytoskeleton organization
regulation of developmental process
regulation of cellular metabolic process
REACTOME

Chromatin modifying enzymes
RORA activates gene expression
Regulation of RAS by GAPs
Regulation of Hypoxia-inducible Factor (HIF) by oxygen
BMAL1:CLOCK,NPAS2 activates circadian gene expression
Transcriptional regulation by RUNX1
Signaling by NOTCH4
Circadian Clock
TCF dependent signaling in response to WNT
PKMTs methylate histone lysines
MAPK family signaling cascades
Vif-mediated degradation of APOBEC3G
RAF/MAP kinase cascade
Transcriptional regulation by RUNX3

false discovery
rate
0.0049
0.0049
0.0049
0.0049
0.0049
0.0118
0.0184
0.0184
0.0184
0.0184
0.0196
0.0196
0.0203
0.0212
0.0218
0.0218
0.0218
0.0226
0.0226
0.0265
false
discovery
rate
1.51E-05
8.42E-05
9.85E-05
0.00014
0.00017
0.00017
0.00017
0.00066
0.0008
0.0014
0.0014
0.0016
0.0016
0.0016
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